Expression of rolGLP-HV in E. coli and its Dual-Function for the Treatment of Diabetes and Thrombosis
详细信息 查看全文
- 作者：Yaofang Zhang (1)
Yiming Wei (2)
Baicheng Ma (1)
Kunyan Qiao (1)
Zhihua Ma (1)
Chong Li (1)
Chao Ma (1)
Yanli Ji (1)
Zhen Dong (1)
Junfeng Hao (1)
Peipei Tu (1)
Jian-Hong Zhu (3)
Minggang Li (1) - 关键词：Diabetes mellitus ; Diabetes complications ; rolGLP ; HV fusion gene ; Thrombosis
- 刊名：International Journal of Peptide Research and Therapeutics
- 出版年：2013
- 出版时间：September 2013
- 年：2013
- 卷：19
- 期：3
- 页码：257-263
- 全文大小：368KB
- 参考文献：1. Ajjan RA, Ariens RA (2009) Cardiovascular disease and heritability of the prothrombotic state. Blood Rev 23:67-8 CrossRef
2. Ajjan R, Grant PJ (2006) Coagulation and atherothrombotic disease. Atherosclerosis 186:240-59 CrossRef
3. Aronson D (2008) Hyperglycemia and the pathobiology of diabetic complications. Adv Cardiol 45:1-6 CrossRef
4. Baskova IP, Cherkesova DU, Mosolov VV (1983) Hirudin from leech heads and whole leeches and ‘pseudo-hirudin-from leech bodies. Thromb Res 30:459-67 CrossRef
5. Bell GI, Sanchez-Pescador R, Laybourn PJ, Najarian RC (1983) Exon duplication and divergence in the human preproglucagon gene. Nature 304:368-71 CrossRef
6. Chang JY (1994) Controlling the speed of hirudin folding. Biochem J 30:643-50
7. Deacon CF, Wamberg S, Bie P, Hughes TE, Holst JJ (2002) Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs. J Endocrinol 172:355-62 CrossRef
8. Dou WF, Xu ZH, Zhang XM, Xu HY, Lei JY, Jin J (2011) Pharmacokinetics and biodistribution of 125I labeled rh (GLP-1A2G)2-HSA in mouse following a single subcutaneous injection. Chin Pharmacol Bull 27(1):59-2
9. Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696-705 CrossRef
10. Ferroni P, Basil S, Falco A, Davi G (2004) Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2:1282-291 CrossRef
11. Frokjaer S, Otzen DE (2005) Protein drug stability: a formulation challenge. Nat Rev Drug Discov 4:298-06 CrossRef
12. Gault VA, Flatt PR, O’Harte FP (2003) Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes. Biochem Biophys Res Commun 308:207-13 CrossRef
13. Green BD, Liu HK, McCluskey JT, Duffy NA, O’Harte FP, McClenaghan NH, Flatt PR (2005) Function of a long-term, GLP-1 treated, insulin-secreting cell line is improved by preventing DPPIV mediated degradation of GLP-1. Diabetes Obes Metab 7:563-69 CrossRef
14. Hou J, Yan R, Yang L, Wu Z, Wang C, Ding D, Li N, Ma C, Li M (2007a) High-level expression of fusion protein containing 10 tandem repeated GLP-1 analogs in yeast Pichia pastoris and its biological activity in a diabetic rat model. Biosci Biotechnol Biochem 71(6):1462-469 CrossRef
15. Hou J, Yan R, Ding D, Yang L, Wang C, Wu Z, Yu X, Li W, Li M (2007b) Oral administration of a fusion protein containing eight GLP-1 analogues produced in / Escherichia coli BL21 (DE3) in streptozotocin-induced diabetic rats. Biotechnol Lett 29:1439-446 CrossRef
16. Kreymann B, Williams G, Ghatei MA, Bloom SR (1987) Glucagon-like peptide-1 7-6: a physiological incretin in man. Lancet 2:1300-303 CrossRef
17. Markwardt F (1989) Development of hirudin as an antithrombotic agent. Semin Thromb Hemost 15:269-82 CrossRef
18. Markwardt F (1994) The development of hirudin as an antithrombotic drug. Thromb Res 74:1-3 CrossRef
19. Meyer BJ, Badimon JJ, Chesebro JH, Chesebro JH, Fallon JT, Fuster V, Badimon L (1998) Dissolution of mural thrombus by specific thrombin inhibition with r-hirudin. Circulation 97:681-85 CrossRef
20. Pospisilik JA, Stafford SG, Demuth HU, Brownsey R, Parkhouse W, Finegood DT, Mcintosh CH, Pederson RA (2002) Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 51:943-50 CrossRef
21. Prisco D, Falciani M, Antonucci E, Gensini GF (2001) Hirudins for prophylaxis and treatment of venous thromboembolism. Semin Thromb Hemost 27:543-49 CrossRef
22. Shah RB, Ahsan F, Khan MA (2002) Oral delivery of proteins: progress and prognostication. Crit Rev Ther Drug Carrier Syst 19:135-69 CrossRef
23. Torchilin VP, Lukyanov AN (2003) Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov Today 8:259-66 CrossRef
24. Turton MD, O’Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J, Bloom SR (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 37:969-72
25. Vahl TP, Patym BW, Fuller BD, Peigeon RL, D’Alessio DA (2003) Effects of GLP-1-(7-6) NH2, GLP-1-(7-7) and GLP-1-(9-6) NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab 88:1772-779 CrossRef
26. Zhang M, Lv XY, Li J, Xu ZG, Chen L (2009) The characterization of high-fat diet and multiple low-dose streptozotocin induced type 2 diabetes rat model. Exp Diabetes Res 2008:7040-045 - 作者单位：Yaofang Zhang (1)
Yiming Wei (2)
Baicheng Ma (1)
Kunyan Qiao (1)
Zhihua Ma (1)
Chong Li (1)
Chao Ma (1)
Yanli Ji (1)
Zhen Dong (1)
Junfeng Hao (1)
Peipei Tu (1)
Jian-Hong Zhu (3)
Minggang Li (1)
1. Key Laboratory for Bioactive Materials of the Ministry of Education, Institute of Molecular Biology, College of Life Science, Nankai University, Tianjin, 300071, China
2. Tianjin International Joint Academy of Biotechnology and Medicine, Tianjin, 300457, China
3. Department of Preventive Medicine, Wenzhou Medical College, Wenzhou, 325035, Zhejiang, China
文摘
Glucagon-like peptide-1 (GLP-1) reduces blood glucose and improves abnormal metabolism caused by hyperglycemia. The formation of thrombus, one of major consequences suffered from diabetes, can be inhibited by the treatment of Hirudin (HV). This study was aimed to develop a fusion peptide which combines functions of GLP-1 and HV to treat diabetes and its complication thrombosis. A rolGLP-HV expression plasmid was constructed and expressed in BL21 (DE3) line of E. coli. The peptide was then purified and analyzed in vitro and in vivo for its anti-thrombosis ability. The results showed that the anti-coagulant activity of rolGLP-HV was about 109?±?1.7?ATU/mL, and the peptide displayed a great ability in reducing thrombosis in a mouse model. The effect of rolGLP-HV on plasma glucose was assessed by daily oral-gavage administration up to 10?days in streptozotocin-induced type 2 diabetic mice. Our results showed that rolGLP-HV treatment decreased (p?<?0.01) plasma glucose level by 41.6 and 55.7?%, respectively, on the 5th and 10th day post the initial oral gavage. Also, rolGLP-HV treatment led to an increase in body weight and decreases in drink level and food intake (p?<?0.05) compared with the control. In conclusion, our data suggest that rolGLP-HV peptide has dual-function in preventing thrombosis and reducing plasma glucose.